Prices – Page 3

Congress Eyes Major PBM Reforms in Year-End Spending Bill

4 months ago talkbio0Tagged Benefit Managers, bipartisan, Congress, Congress (U.S. Legislature), Health care facility, Legislation, PBMs, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, reforms, spending, Translucent, year-end

Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

4 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

5 months ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024

Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy

5 months ago talkbio0Tagged AMD, Attitude, Clinical Trials, Failure (biologic function), File (record), Glycogen storage disease type II, OTLK, Prices, United States Food and Drug Administration

Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing

Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform

6 months ago talkbio0Tagged 2024, Biopharma, Donald Trump, Drug Industry, Drug Pricing Reform, Inflation, Kamala Harris, Mediation, Medicare, presidential election, Prices

Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.